These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 19019500

  • 1. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
    Godeau B, Centre de référence labellisé pour la prise en charge des cytopénies auto-immunes de l'adulte.
    Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
    [No Abstract] [Full Text] [Related]

  • 2. Two new drugs for chronic ITP.
    Med Lett Drugs Ther; 2009 Feb 09; 51(1305):10-1. PubMed ID: 19197233
    [Abstract] [Full Text] [Related]

  • 3. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R.
    Am J Hematol; 2016 May 09; 91(5):E293-5. PubMed ID: 26910388
    [Abstract] [Full Text] [Related]

  • 4. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
    Arumugaswamy A, He S, Quach H, Brotchie J, Grigg A.
    Intern Med J; 2014 May 09; 44(5):519-21. PubMed ID: 24816314
    [No Abstract] [Full Text] [Related]

  • 5. Orphan disease gains second treatment option.
    Morrow T.
    Manag Care; 2009 Jan 09; 18(1):47-9. PubMed ID: 19186672
    [No Abstract] [Full Text] [Related]

  • 6. Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia.
    Álvarez Román MT, Fernández Bello I, Arias-Salgado EG, de Paz R, Jiménez Yuste V, Martín Salces M, Butta NV.
    Br J Clin Pharmacol; 2014 Sep 09; 78(3):674-6. PubMed ID: 24602175
    [No Abstract] [Full Text] [Related]

  • 7. [New therapeutic possibilities in chronic ITP in adults].
    Jönsson S, Olsson B, Wadenvik H.
    Lakartidningen; 2014 Sep 09; 106(21-22):1476-9. PubMed ID: 19579436
    [No Abstract] [Full Text] [Related]

  • 8. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H, Kuter DJ.
    Br J Haematol; 2018 Oct 09; 183(2):168. PubMed ID: 29978577
    [No Abstract] [Full Text] [Related]

  • 9. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
    Magnano L, Enríquez H, Esteve J, Cervera R, Espinosa G.
    J Rheumatol; 2014 Sep 09; 41(9):1895-6. PubMed ID: 25179983
    [No Abstract] [Full Text] [Related]

  • 10. Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series.
    Poston JN, Gernsheimer TB.
    Int J Hematol; 2019 Aug 09; 110(2):255-259. PubMed ID: 30972617
    [Abstract] [Full Text] [Related]

  • 11. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
    González KJ, Zuluaga SO, DaRos CV, Rodríguez PP, Martí AC.
    Ann Hematol; 2017 Mar 09; 96(3):507-508. PubMed ID: 27975127
    [No Abstract] [Full Text] [Related]

  • 12. [Development of thrombopoietin receptor agonists].
    Miyakawa Y.
    Rinsho Ketsueki; 2009 Oct 09; 50(10):1434-43. PubMed ID: 19915352
    [No Abstract] [Full Text] [Related]

  • 13. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
    Neunert CE.
    Hamostaseologie; 2019 Aug 09; 39(3):272-278. PubMed ID: 30646404
    [Abstract] [Full Text] [Related]

  • 14. What is publication? The case of eltrombopag.
    Benham L, Guo L, Turner R.
    Lancet; 2011 Jan 29; 377(9763):360-1. PubMed ID: 21277427
    [No Abstract] [Full Text] [Related]

  • 15. [Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim].
    Rodríguez Vargas B, Serna Pérez J, Bermejo Vicedo T.
    Farm Hosp; 2013 Jan 29; 37(3):265-6. PubMed ID: 23789804
    [No Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S, Nakaseko C, Takeuchi M, Kumagai K, Komatsu T, Tanaka H, Hara S, Koizumi M, Imai H, Yokota A, Takeuchi M, Inokuchi K, Matsuura Y, Aotsuka N, Wakita H.
    Br J Haematol; 2013 Oct 29; 163(2):286-9. PubMed ID: 23862773
    [No Abstract] [Full Text] [Related]

  • 17. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
    Neunert CE, Rose MJ.
    Blood Adv; 2019 Jun 25; 3(12):1907-1915. PubMed ID: 31239245
    [Abstract] [Full Text] [Related]

  • 18. New options after first-line therapy for chronic immune thrombocytopenic purpura.
    Burzynski J.
    Am J Health Syst Pharm; 2009 Jan 15; 66(2 Suppl 2):S11-21. PubMed ID: 19139486
    [Abstract] [Full Text] [Related]

  • 19. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.
    Ruggeri M.
    Am J Hematol; 2012 Oct 15; 87(10):946-7. PubMed ID: 22847498
    [No Abstract] [Full Text] [Related]

  • 20. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.
    Piccin A, Amaddii G, Natolino F, Billio A, Cortelazzo S.
    Blood Transfus; 2014 Jan 15; 12 Suppl 1(Suppl 1):s149-50. PubMed ID: 23736912
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.